Ascentage Pharma signs exclusive option agreement with Takeda for global license of olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor.
Ascentage Pharma has signed an exclusive option agreement with Takeda to enter into a global license for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor. Ascentage will receive a $100 million option payment and may receive up to $1.2 billion in milestone payments and royalties on annual sales. Takeda will purchase a minority interest in Ascentage Pharma. Olverembatinib is in development for chronic myeloid leukemia and other hematological cancers.
June 14, 2024
6 Articles